Skip To Main Content
Yeow Tee Goh on Muck Rack

Yeow Tee Goh

As seen in: Nature, MDPI, Future Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yeow Tee

Contact Yeow Tee, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results | Leukemia

|
By Andreas Hochhaus Verified, Dong-Wook Kim, Jorge Cortés, Koji Sasaki, Michael J. Mauro, Timothy Hughes, Massimo Breccia, Moshe Talpaz, Yeow Tee Goh, Daniel DeAngelo, Fabian Lang, Michael C. Heinrich, Meng Cao
| Nature Verified
Abstract Asciminib is the first approved BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP). The present final analysis of the phase 1, open-label, nonrandomized trial (NCT02081378) assessed the long-term safety, tolerability, and antileukemic activity of asciminib in 115 patients with chronic myeloid leukemia in chronic phase without the BCR::ABL1T315I mutation who received asciminib 10–200 mg twice daily (BID) or 80–200 mg once daily (cutoff: March 14, 2023).
Open in Who Shared View Duplicates (2) Issue with article?

Fusion Genes in Myeloid Malignancies

|
By Chieh Hwee Ang, Hein Than, Yeow Tee Goh, Tertius T. Tuy
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?

Daratumumab-Based Therapeutic Approaches and Clinical Outcomes in Multiple Myeloma and other Plasma Cell Dyscrasias: Insights from a Nationwide Real-World Chart Review Study | Published in Clinical Hematology International

|
By Wee Joo Chng, Yeow Tee Goh, Melissa Ooi, Yunxin Chen
| scholasticahq.com
Background Multiple myeloma accounts for about 2% of all malignancies and 10% of hematological cancers, primarily affecting the elderly, with 43% of new cases in the UK occurring in patients aged 75 and over.1 In Singapore, the incidence is around 1.69 per 100,000 people,2 while the rate in Southeast Asia is 0.96 per 100,000.3 Treatment for myeloma has evolved substantially over the decades. In the 1960s, treatment centered on oral melphalan and prednisolone.
Open in Who Shared Issue with article?
See all 9 articles